Download PDF
Horm Metab Res 1987; 19(6): 271-274
DOI: 10.1055/s-2007-1011796
Clinical

© Georg Thieme Verlag, Stuttgart · New York

Absence of Suppressive Effect of Somatostatin on Prolactin Levels in Patients with Hyperprolactinemia

M. D. Bronstein1 , M. Knoepfelmacher2 , B. Liberman3 , R. Marino1  Jr. , O. A. Germek2 , A. V. Schally4
  • 1Neuroendocrine Unit, Division of Functional Neurosurgery, University of São Paulo Medical School, São Paulo, Brazil
  • 2Endocrine Unit, Hospital das Clínicas, São Paulo, Brazil
  • 3Endocrine Unit, Hospital Brigadeiro, INAMPS, São Paulo, Brazil
  • 4Endocrine and Polypeptide Laboratories, Veterans' Administration Hospital, New Orleans, Louisiana, U.S.A.
Further Information

Publication History

1984

1986

Publication Date:
14 March 2008 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

The effect of somatostatin (SRIF: 10 ug/min during 120 min) on serum prolactin (PRL) levels was studied in eleven patients with hyperprolactinemia of varying causes: 2 patients with acromegaly; 2 with primary hypothyroidism; 4 with prolactinoma and 3 with drug (sulpiride) induced hyperprolactinemia.

During SRIF infusion, no significant change in PRL levels was observed in any of the 4 groups studied except in one female patient with a prolactinoma.

The biological activity of SRIF was demonstrated by the significant inhibition (P < 0.05) of insulin levels seen in all 11 patients (52% fall in relation to basal) without simultaneous modification of glycemia.

These data suggest that SRIF does not decrease PRL secretion in most patients with hyperprolactinemia.

Key-Words

Somatostatin - Hyperprolactinemia - Drug Induced - Hypothyroidism - Acromegaly - Prolactinoma

      >